

NEWS

Contact

Gualberto Ruaño, M.D., Ph.D.
President and Chief Executive Officer
Genomas, Inc.
860-545-4574



FOR IMMEDIATE RELEASE
JANUARY 26, 2005

GENOMAS APPOINTS CHIEF TECHNOLOGY OFFICER AND CHIEF BIostatISTICS CONSULTANT

HARTFORD, CT – Genomas, Inc., a biomedical company advancing personalized medicine, announced today the appointment of Andreas Windemuth, Ph.D., as Chief Technology Officer and Theodore Holford, Ph.D., as Chief Biostatistical Consultant.

Dr. Windemuth has worked in the field of computational biology for 15 years. Previously, Dr. Windemuth has had a distinguished career in bioinformatics for 9 years at two New Haven-based biotechnology companies, CuraGen Corporation and most recently, Genaissance Pharmaceuticals, Inc. He obtained his Ph.D. in Theoretical Physics from the Technical University of Munich. He was Post-doctoral research scientist in the Department of Biochemistry and Molecular Biophysics at Columbia University. Dr. Windemuth is a fellow of the Boehringer Ingelheim Fonds (Stuttgart, Germany). He has published on genetic associations to disease susceptibility and drug responses, on correlation of gene expression and gene variability, on linkage disequilibrium mapping of DNA polymorphisms and on the statistical predictive power of genetic markers.

Dr. Holford is Susan Dwight Bliss Professor of Public Health (Biostatistics), Professor of Statistics, and Head of the Division of Biostatistics at Yale University. The fields in which he has collaborated and used his methods include cancer epidemiology, perinatal epidemiology, environmental health sciences, spinal cord injury studies, psychiatry, geriatrics and pediatrics. He is one of the founding editors of “Statistical Methods in Medical Research” and recently published “Multivariate Methods in Epidemiology” a textbook on statistical methods in epidemiological research. He has made significant methodological contributions to multivariate analysis of matched studies, log-linear models for survival, analysis of time trends for disease, and population models for disease trends.

Dr. Gualberto Ruaño, M.D., Ph.D., President and Chief Executive Officer of Genomas, stated: “Learning from variability in response to various treatments ranging from exercise to drug therapy, and translating that knowledge into predictive DNA markers for personalized medicine is the key asset of Genomas. Positioning each individual along a continuum of response based on physiological and genetic markers is the key deliverable to the physician as we commercialize our technology. We are privileged to have Dr. Windemuth, with his industry experience in computational biology and statistical modeling, to direct the development of our PhysioGenomics™ technology, and Dr. Holford, one of the world’s leading experts in biostatistics, to facilitate its transition to clinically predictive markers. These appointments are consistent with our goal of bringing simply the best science to the field of personalized medicine. I am proud we could attract talent of such stature to our company as we advance genomics to health care delivery.”

ABOUT GENOMAS

Genomas Inc. is developing PhysioType™ Products to personalize health. PhysioTypes are revolutionary healthcare diagnostics, empowering physicians with unprecedented capabilities to prescribe personalized and highly effective preventive treatments incorporating diet, exercise and drug regimens for each patient. Genomas’ product development focus is metabolic syndrome and associated disorders (obesity, diabetes, cardiovascular disease). Genomas has established a partnership in genomic medicine with Hartford Hospital, and is located on its campus in downtown Hartford, CT. *For more information please access the company’s web site at www.genomas.net*

###